Idecabtagene vicleucel (Abecma)
Jump to navigation
Jump to search
Mechanism of action
Anti-BCMA CAR T-cells.
Diseases for which it is used
History of changes in FDA indication
- 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Patient Drug Information
Also known as
- Code name: bb2121
- Generic name: ide-cel
- Brand name: Abecma